当前位置:公众访问 >页面
简体中文 / English
1.Screening
1.1.Inclusion Criteria

Meet option 1 and 2 or option 1 and 3:

Primary lung cancer patients with pathological diagnosis and without clinical treatment or patients with pulmonary lesions highly suspicious for lung cancer and without prior treatment

1.2.Exclusion Criteria

Without diseases as listed following:

Diabetes
/
Other malignant tumors except lung cancer
/
Asthma
/
Severe liver dysfunction
/
End-stage renal disease
/
Acute inflammation

1.3.Informed Consent Form Signature

Inform Consent Form Signature

Yes

2.Baseline
2.1.General information
2.2.1.2.1.1、Case Number/ID Number

Case Number/ID Number

366245

2.2.1.2.1.2、Name

Name

LXHU

2.2.1.2.1.3、Gender

Gender

Female

2.2.1.2.1.4、Age

Age

48

2.2.1.2.1.5、Height

Height

156 cm

2.2.1.2.1.6、Weight

Weight

51.5 kg

2.2.1.2.1.7、Education

Education

University

2.2.1.2.1.8、Own Phone Number

Own Phone Number

18160098877

2.2.1.2.1.9、Relatives Phone Number

Relatives Phone Number

2.2.1.2.1.10、Relatives Name

Relatives Name

2.2.Past History
2.2.2.2.2.1、Smoking History

Smoking History

No

2.2.2.2.2.2、Drinking History

Drinking History

No

2.2.2.2.2.3、Surgical History

Surgical History

No

2.2.2.2.2.4、Family Cancer History

Family Cancer History

No

2.2.2.2.2.5、Comorbidity

Comorbidity

No

2.2.2.2.2.6、Pulmonary Nodules on Past Chest CT

Pulmonary Nodules on Past Chest CT

Not Done

2.3.Exhaled Breath Collection Person

Exhaled Breath Collection Person

ZXZ

2.4.Exhaled Breath Collection Date

Exhaled Breath Collection Date

2019-12-02 yyyy-mm-dd

2.5.Data Entry Clerk

Data Entry Clerk

ZXZ

2.6.Data Entry Date

Data Entry Date

2019-12-02 yyyy-mm-dd

2.7.Quality Control Person

Quality Control Person

2.8.Quality Control Date

Quality Control Date

yyyy-mm-dd

3.Auxiliary Examination For Lung Cancer Subject Only
3.1.Tumor Marker

Tumor Marker Increase

3.2.FVC

FVC

2.54 L

3.3.FVC%

FVC%

91.6 %

3.4.FEV1

FEV1

2.04 L

3.5.FEV1%

FEV1%

86.2 %

3.6.FEV1/FVC

FEV1/FVC

80.19 %

3.7.MVV%

MVV%

108.8 %

3.8.DLCO SB%

DLCO SB%

106.5 %

3.9.Tumor Shape on Chest CT

Tumor Shape on Chest CT

Ground Glass Nodule

3.10.Tumor Maximum Diameter on Chest CT

Tumor Maximum Diameter on Chest CT

1.2 cm

3.11.Lymph Node on Chest CT

Lymph Node on Chest CT

cN1-2(-)

3.12.PET-CT

PET-CT SUVmax

Not Done

4.Treatment For Lung Cancer Subject Only
4.1.Surgery
4.4.1.4.1.1、Tumor Location

Tumor Location

Left Upper Lobe

4.4.1.4.1.2、Surgical Approach

Surgical Approach

VATS Converts to Thoracotomy

4.4.1.4.1.3、Type of Resection

Type of Resection

Segmentectomy

4.4.1.4.1.4、Operative Time

Operative Time

210 minutes

4.4.1.4.1.5、Intraoperative Blood Loss

Intraoperative Blood Loss

1700 ml

4.4.1.4.1.6、Intraoperative Blood Transfusion

Intraoperative Blood Transfusion

Yes

4.4.1.4.1.7、Surgeon Name

Surgeon Name

Xiaojun Yang

4.4.1.4.1.8、Surgical Margin

Surgical Margin

No Residual Tumor

4.4.1.4.1.9、Pathological Type

Pathological Type

MIA

4.4.1.4.1.10、Lymphovascular Invasion

Lymphovascular Invasion

No

4.4.1.4.1.11、Perineural Invasion

Perineural Invasion

No

4.4.1.4.1.12、Gene Mutation

Gene Mutation

Not Done

4.4.1.4.1.13、pT Stage

pT Stage, Eighth Edition

T1b

4.4.1.4.1.14、pN Stage

pN Stage, Eighth Edition

N0

4.4.1.4.1.15、Stations of N1 Lymph Nodes

Stations of N1 Lymph Nodes

Two Stations

4.4.1.4.1.16、Numbers of N1 Lymph Nodes

Numbers of N1 Lymph Nodes

3

4.4.1.4.1.17、Numbers of Metastatic N1 Lymph Nodes

Numbers of Metastatic N1 Lymph Nodes

0

4.4.1.4.1.18、Stations of N2 Lymph Nodes

Stations of N2 Lymph Nodes

Three Stations

4.4.1.4.1.19、Numbers of N2 Lymph Nodes

Numbers of N2 Lymph Nodes

3

4.4.1.4.1.20、Numbers of Metastatic N2 Lymph Nodes

Numbers of Metastatic N2 Lymph Nodes

0

4.4.1.4.1.21、Dissection of Station 7

Dissection of Station 7

Yes

4.4.1.4.1.22、Highest N2 Status

Highest N2 Status

Unknown

4.4.1.4.1.23、Types of Lymph Node Dissection

Types of Lymph Node Dissection

Selective Lymph Node Sampling

4.4.1.4.1.24、pM Stage

pM Stage, Eighth Edition

M0

4.4.1.4.1.25、pTNM Stage

pTNM Stage, Eighth Edition

Stage IA2

4.4.1.4.1.26、Postoperative Complications

Postoperative Complications

Intraoperative Massive Hemorrhage

4.2.Non-Surgical Treatment

Non-Surgical Treatment

4.3.Time point
4.4.3.4.31、Admission Date

Admission Date

2019-11-27 yyyy-mm-dd

4.4.3.4.32、Discharge Date

Discharge Date

2019-12-10 yyyy-mm-dd

4.4.3.4.33、Surgery Date

Surgery Date

2019-12-02 yyyy-mm-dd

5.Exhaled Breath Analysis Data Saved In SCU
5.1.Volatile Organic Compounds

Volatile Organic Compounds